Advaxis Inc. (NASDAQ:ADXS) shares were up 6.2% during mid-day trading on Thursday . The company traded as high as $8.33 and last traded at $8.04, with a volume of 628,713 shares trading hands. The stock had previously closed at $7.57.

A number of research analysts have issued reports on ADXS shares. FBR & Co restated a “positive” rating and issued a $34.00 target price on shares of Advaxis in a report on Tuesday, March 29th. HC Wainwright restated a “buy” rating on shares of Advaxis in a report on Thursday, April 21st. Finally, Jefferies Group restated a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Six research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $24.80.

The company’s market capitalization is $269.62 million. The company’s 50-day moving average price is $8.40 and its 200-day moving average price is $8.00.

In other news, CEO Daniel O’connor sold 8,237 shares of the firm’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $7.51, for a total transaction of $61,859.87. Following the transaction, the chief executive officer now directly owns 316,661 shares of the company’s stock, valued at $2,378,124.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas J. Mckearn sold 4,100 shares of the firm’s stock in a transaction on Friday, May 13th. The shares were sold at an average price of $7.45, for a total value of $30,545.00. Following the transaction, the director now directly owns 82,120 shares in the company, valued at $611,794. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.